Cancer Archives

News and Trends 10 Nov 2015

What the FUGT? We tried the Algae Bar Beer for the TransArt Fest in Copenhagen!

We went to the TransArt Festival at the stunning ‘Dome of Visions‘ in Copenhagen on Friday. There, we met loads of scientists and members of the public who were just as entranced as us by the home-grown BioArt. After our blogger Julie covered the Fab Foundation’s ‘Biohacking’ movement last Monday, I was really intrigued by […]

November 10, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 9 Nov 2015

Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer

Cell-based Immune-oncology therapies continue to deliver amazing results. After Cellectis wondersaving from last week, Oxford’s Adaptimmune has some surprisingly good results too. Adaptimmune is a British, Oxford-based immuno-oncolgy company. It held a massive IPO last year, raising up to €150M on the NASDAQ, and its CEO was interviewed by BIO (video here) where he seemed […]

November 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 6 Nov 2015

Cellectis’ Miraculous Saving of a Baby Girl. What’s the impact on the CAR-T field?

About 30%. That’s how Cellectis‘ NASDAQ stock price has jumped between the 4th and the 5th of November. But why? Basically, because of the first human success of their allogeneic CAR-T therapy! The Great Ormond Street Hospital (UK) treated a young patient with refractory relapsed Acute Lymphoblastic Leukemia (ALL) with Cellectis’ allogeneic UCART19 product candidate in June. To […]

November 6, 2015 - 2 minutesmins - By Jerome Topsent

News and Trends 4 Nov 2015

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Sanofi is now the latest Biotech lining up to partner with BioNTech from Mainz (Germany), for license of their mRNA Immuno-oncology platform in a€1.37Bn long-term development deal. Novel mRNA targets in Immuno-onology is a top-shelf cancer R&D area, with Germany’s CureVac also attracting another €100M yesterday for their mRNA platform (which targets lung and prostate […]

November 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 3 Nov 2015

Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech

This is the third interview we publish from BIO (yes, we are working hard). It comes after the interview of Simon Moroney, CEO of MorphoSys and Jane Dancer, CBO of F-star. Medigene is another big/famous Biotech company of Munich, Germany. It was founded over 20 years ago and is now specialised in cell-based therapies. It counts […]

November 3, 2015 - 1 minutemin - By Philip Hemme

News and Trends 3 Nov 2015

€100 Million Investment Round Prepares CureVac For Vaccine Expansion

“The RNA People” at CureVac in Tübingen (Germany) have a new €100M investment into their RNA platform, which has prophylactic purposes for common viruses, pipeline candidates for prostate cancer, lung cancer and research into vaccines for HIV, Tuborculosis and Rabies. Indeed, the financial success surrounding their mRNA work has been startlingly impressive, with the EU […]

November 3, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 3 Nov 2015

Exclusive from BIO-Europe 2015: Interview with F-star, a Cambridge-UK Immuno-oncology Biotech

Second interview of BIO-Europe 2015. This time, it’s a British company from Cambridge (UK): F-star. This morning we spoke with their CBO Jane Dancer. F-star is developing bi-specific antibodies for immuno-oncology and inflammatory disease. It has raised a total of 38 million euros from top EU VCs. Jane Dancer’s business tenure within the field is […]

November 3, 2015 - 1 minutemin - By Philip Hemme

News and Trends 30 Oct 2015

Purple GMO Tomatoes are Growing Medicines in the UK

Meet the purple tomatoes which produce as much Revervesterol in a single fruit as 50 bottles of wine, and as much anti-breast cancer chemical as 2.5Kg of Tofu! The John Innes Centre in Norwich (East England) have engineered these tomato plants to produce larger amounts of these health-related compounds. With funding from the Biotechnology and […]

October 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 29 Oct 2015

Cellectis UCART Milestone: One step closer to a Universal CAR-T Therapy for Blood Cancer

Cellectis is a leader in immuno-oncology CAR-T therapies from France, which might revolutionise cancer treatments. Now, the next step in the CAR-T campaign is to step away from personalised (autologous) therapies, which are time-consuming and expensive, to instead produce an allogenic version available to all. So, what is CAR-T? You can read a more in-depth […]

October 29, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 29 Oct 2015

ERRATUM: Celyad’s US patent on TCR-deficient allogeneic CAR-T cells

ERRATUM: I published a first article on Celyad’s new patent on last Tuesday where I made an error of judgement. Celyad’s US patent covers allogeneic CAR-T modified to reduce immunogenicity. In my previous article, I wrote that Celyad stated having obtained the first US patent on CAR-T, which is wrong. Last Tuesday, Celyad announced having […]

October 29, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 26 Oct 2015

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

Amgen is now months away from a European approval with Imlygic (also known as T-VEC) – the first oncolytic immunotherapy for advanced melanoma. The Committee for Medicinal Products for Human Use (CHMP) and the scientific committee of the European Medicines Agency (EMA), have reacted positively. Melanoma is a type of skin cancer that is characterized by the uncontrolled growth of melanocytes, […]

October 26, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 23 Oct 2015

#Sorry: The World-leading Oncology Company fails in Phase III

Antibody Drug Conjugate is a smart way to improve chemotherapy. That is the strategy of Roche / Immunogen‘s drug Kadcyla®, which has just failed in Phase III clinical trial to extend its indications. Here are the facts… Antibody Drug Conjugate is at the boundary between chemical and biological drug. The principle is pretty simple; once the antibody fixes to […]

October 23, 2015 - 2 minutesmins - By Jerome Topsent

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

What the FUGT? We tried the Algae Bar Beer for the TransArt Fest in Copenhagen!

Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer

Cellectis’ Miraculous Saving of a Baby Girl. What’s the impact on the CAR-T field?

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech

€100 Million Investment Round Prepares CureVac For Vaccine Expansion

Exclusive from BIO-Europe 2015: Interview with F-star, a Cambridge-UK Immuno-oncology Biotech

Purple GMO Tomatoes are Growing Medicines in the UK

Cellectis UCART Milestone: One step closer to a Universal CAR-T Therapy for Blood Cancer

ERRATUM: Celyad’s US patent on TCR-deficient allogeneic CAR-T cells

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

#Sorry: The World-leading Oncology Company fails in Phase III

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!